Get a free sample of U.S. Cancer Contrast Media Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of U.S. Cancer Contrast Media Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
U.S. Cancer Contrast Media Market Size
U.S. Cancer Contrast Media Market size was valued at USD 2.4 billion in 2023 and is estimated to grow at a CAGR of 4.9% between 2024 and 2032. Cancer contrast media refers to specialized contrast agents or dyes used in medical imaging procedures specifically aimed at diagnosing, staging, or monitoring cancer. These contrast media are designed to enhance the visualization of cancerous tissues, tumors, and associated structures during imaging studies such as computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and ultrasound.
The increasing prevalence of cancer cases has emerged as a significant driver for the market. For instance, according to the American Cancer Society in 2021, there were an estimated 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in the U.S. Therefore, there is a rising need for effective treatments such as chemotherapy, radiation therapy, immunotherapy to address the complexities of managing cancer-related issues.
Furthermore, growing technological advancements in cancer contrast imaging such as MRI contrast media, which is set to reach USD 2.5 billion by 2032, increasing number of clinical studies, among other contributing factors are anticipated to propel the industry growth.
Who are the leading players operating in the U.S. cancer contrast media market?
Some of the top cancer contrast media companies in the U.S. include Bayer AG, Bracco Imaging S.p.A., GE Healthcare Technologies Inc, Guerbet, iMAX Diagnostic Imaging, Lantheus Medical Imaging, nanoPET Pharma GmbH, Subtle Medical, Inc., Telix Pharmaceuticals Limited, and Trivitron Healthcare.
Why is the demand for CT scans increasing in the U.S.?
The CT scan segment is projected to account for USD 1.2 billion in revenue by 2032, owing to its increasing use for monitoring the response to cancer treatment longitudinally and getting detailed insights into treatment efficacy and progression.
How big is the U.S. cancer contrast media market?
The market size of U.S. cancer contrast media reached USD 2.4 billion in 2023 and is set to witness 4.9% CAGR during 2024 to 2032, propelled by the increasing prevalence of cancer coupled with the growing technological advancements.
Why is the use of cancer contrast media growing in breast cancer treatment in the U.S.?
U.S. cancer contrast media industry from breast cancer application segment accounted for 24.1% revenue share in 2023, due to the rising prevalence of breast cancer in the U.S.